Orchestra BioMed Holdings, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Orchestra BioMed Holdings, Inc. (OBIO) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$3.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$253.00K, a 123.21% decline year-over-year.
- Orchestra BioMed Holdings, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.06M.
- Orchestra BioMed Holdings, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $566.00K.
- Orchestra BioMed Holdings, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $3.41M, a 176.95% increase year-over-year.
- Orchestra BioMed Holdings, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $4.87M, a 63.89% increase from fiscal 2024.
- Orchestra BioMed Holdings, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $2.97M, a 1947.59% increase from fiscal 2023.
- Orchestra BioMed Holdings, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $145.00K, a 95.67% decline from fiscal 2022.
- Orchestra BioMed Holdings, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $3.35M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$253.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$3.31M 10-Q · filed 2026-08-10 | -$2.75M derived: sum of 3 quarters · filed 2026-08-10 | $667.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$3.06M 10-Q · filed 2026-05-12 | -$2.49M derived: sum of 2 quarters · filed 2026-05-12 | $920.00K derived: sum of 3 quarters · filed 2026-05-12 | $2.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.98M derived: sum of 2 quarters · filed 2026-03-12 | $5.07M derived: sum of 3 quarters · filed 2026-08-10 | $4.87M 10-K · filed 2026-03-12 |
| 2025-09-30 | $3.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.50M derived: sum of 2 quarters · filed 2026-08-10 | $4.30M 10-Q · filed 2025-11-10 | $3.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $888.00K 10-Q · filed 2026-08-10 | $176.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.41M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$202.00K 10-Q · filed 2026-05-12 | -$914.00K derived: sum of 2 quarters · filed 2026-05-12 | $318.00K derived: sum of 3 quarters · filed 2026-05-12 | $4.04M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$712.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $520.00K derived: sum of 2 quarters · filed 2026-03-12 | $4.25M derived: sum of 3 quarters · filed 2026-03-12 | $2.97M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.96M derived: sum of 2 quarters · filed 2025-11-10 | $3.68M 10-Q · filed 2025-11-10 | $4.17M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.45M 10-Q · filed 2025-08-12 | $2.94M derived: sum of 3 quarters · filed 2025-08-12 | $3.61M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$1.28M 10-Q · filed 2025-05-12 | -$784.00K derived: sum of 2 quarters · filed 2025-05-12 | -$116.00K derived: sum of 3 quarters · filed 2025-05-12 | $663.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.16M derived: sum of 2 quarters · filed 2025-03-31 | $1.94M derived: sum of 3 quarters · filed 2025-03-31 | $145.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $668.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.45M derived: sum of 2 quarters · filed 2024-11-12 | -$348.00K 10-Q · filed 2024-11-12 | $710.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $779.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$1.02M 10-Q · filed 2024-08-12 | $42.00K derived: sum of 3 quarters · filed 2024-08-12 | $1.66M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$1.79M 10-Q · filed 2024-05-13 | -$737.00K derived: sum of 2 quarters · filed 2024-05-13 | $885.00K derived: sum of 3 quarters · filed 2024-05-13 | $1.35M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $2.68M derived: sum of 2 quarters · filed 2024-03-27 | $3.15M derived: sum of 3 quarters · filed 2024-03-27 | $3.35M 10-K · filed 2024-03-27 |
| 2022-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.09M derived: sum of 2 quarters · filed 2023-11-13 | $2.29M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $470.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $672.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $202.00K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |